Fig. 3From: Cost-effectiveness analysis of cabazitaxel for metastatic castration resistant prostate cancer after docetaxel and androgen-signaling-targeted inhibitor resistanceThe cost-effectiveness acceptability curves for probabilistic sensitivity analyses. QALY, quality-adjusted life year; WTP, willingness-to-payBack to article page